Lentigo Maligna Clinical Trial
Official title:
An Open Monocentric Pilot Study to Investigate the Potential of Imiquimod 5% Cream to Detect Residual and to Prevent Recurrence of Lentigo Maligna After Surgical Excision
Verified date | August 2019 |
Source | Medical University of Graz |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a prospective, longitudinal, uncontrolled study with follow-up for 5 years.Patients having undergone surgical excision of lentigo maligna (LM) or lentigo maligna melanoma (LMM) will be invited to this study. Eligible patients will start treatment with imiquimod 6 weeks after the excision, the treatment will last for up to 12 weeks. Inflammatory reactions and the occurrence of residual lesions will be documented. The healing effect will be determined (initial clearance rate) 20 weeks after start of treatment with imiquimod. All patients who were enrolled (=exposed to imiquimod in this study) will be followed up for 5 years or until recurrence of the LM or LMM
Status | Active, not recruiting |
Enrollment | 60 |
Est. completion date | December 2021 |
Est. primary completion date | December 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Age > 18 years - Having undergone surgical excision of LM or LMM - Positive histological finding of LM or LMM (positive histology of primary excision) Exclusion Criteria: - History of allergic reaction to imiquimod or its excipients. - Pregnancy, breast-feeding or planned pregnancy during the study and women of child-bearing potential not using adequate contraception. Women of child bearing potential not using a highly effective method of birth control defined as those which result in a low failure rate (i.e. <1% per year) when used consistently and correctly such as implants, injectables, combined oral contraceptives, hormonal IUDs, tubal ligation or vasectomised partner - History of malignant melanoma having metastasised or where metastasis could be expected - Other malignant tumours in the study treatment area (exception actinic keratosis (AK)) - Lack of ability or willingness to give informed consent - Lack of willingness to have personal study related data collected, archived or transmitted according to protocol - Anticipated non-availability for study visits/procedures |
Country | Name | City | State |
---|---|---|---|
Austria | Medical University of Graz | Graz | |
Austria | Medical University of Graz, Dept. Dermatology | Graz |
Lead Sponsor | Collaborator |
---|---|
Medical University of Graz |
Austria,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Elimination of possible subclinical lesions of LM that resides after surgical excision by determining the long-term recurrence rates. | 60 months | ||
Secondary | Incidence of subclinical residual lesions and local skin reactions. | 20 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT06046144 -
Comparison of 3 in Vivo Microscopic Imaging Techniques for the Diagnosis of Pigmented Tumors
|
||
Completed |
NCT00707174 -
Combination Therapy With Imiquimod Cream 5% and Tazarotene Cream 0.1% for the Treatment of Lentigo Maligna
|
N/A | |
Completed |
NCT03508297 -
Reflectance Confocal Microscopy to Diagnose MM & LM
|
||
Withdrawn |
NCT02306512 -
Mohs and Immunofluorescence for Malignant Melanoma In Situ
|
N/A | |
Completed |
NCT01161888 -
Effect of Topical Imiquimod on Lentigo Maligna
|
Phase 4 | |
Completed |
NCT02723721 -
Prospective Study of Ingenol Mebutate for Non-invasive Lentigo Melanoma of the Face
|
Phase 2 | |
Terminated |
NCT04688749 -
Use of Electrical Impedance Spectroscopy (EIS) for Early Diagnosis of Skin Damage
|
||
Completed |
NCT02685592 -
Photodynamic Therapy for Lentigo Maligna Using 5-aminolevulinic Acid Nanoemulsion as a Light Sensitizing Cream
|
Phase 4 | |
Completed |
NCT02394132 -
Radiotherapy or Imiquimod in Complex Lentigo Maligna
|
Phase 3 | |
Completed |
NCT00785369 -
In Vivo Confocal Microscopy for Pigmented Lesion Diagnosis
|
N/A | |
Recruiting |
NCT06014619 -
Complications and Recurrences After Mohs Micrographic Surgery and Slow Mohs
|